SCHEMBL176355

SCHEMBL176355

C[N+](C)(C)CCOP(=O)([O-])OCC(=O)O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.56
AKT1 P31749 2/20 0.56
ESR1 P03372 1/20 0.56
ADORA3 P0DMS8 1/20 0.56
CDC25A P30304 1/20 0.56
AGTR1 P30556 1/20 0.56
ADRA1A P35348 1/20 0.56
KCNH2 Q12809 1/20 0.56
SMN1; SMN2 Q16637 3/20 0.55
RECQL P46063 1/20 0.45
ADRA1D P25100 1/20 0.45
PTAFR P25105 1/20 0.45
HTR1D P28221 1/20 0.45
HTR2C P28335 1/20 0.45
ADRA1B P35368 1/20 0.45
DRD3 P35462 1/20 0.45
TMEM97 Q5BJF2 1/20 0.45
PRKD3 O94806 1/20 0.43
PRKCG P05129 1/20 0.43
PRKCB P05771 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21631754 0.80 LMNA (0.67) LMNAAKT1ESR1ADORA3CDC25A
SCHEMBL3135948 0.80 FABP3 (0.42) LMNAAKT1ESR1ADORA3CDC25A
SCHEMBL8911477 0.80 LMNA (0.53) LMNAAKT1ESR1ADORA3CDC25A
SCHEMBL1853865 0.79 SMN1; SMN2 (0.70) LMNAAKT1ESR1ADORA3CDC25A
SCHEMBL5476581 0.79 SMN1; SMN2 (0.49) LMNAAKT1ESR1ADORA3CDC25A
SCHEMBL19734900 0.77 SMN1; SMN2 (0.60) LMNAAKT1ESR1ADORA3CDC25A
SCHEMBL20090040 0.77 LMNA (0.62) LMNAAKT1ESR1ADORA3CDC25A
SCHEMBL4972574 0.77 LMNA (0.86) LMNAAKT1ESR1ADORA3CDC25A
SCHEMBL26756555 0.77 LMNA (0.73) LMNAAKT1ESR1ADORA3CDC25A
SCHEMBL8911167 0.77 LMNA (0.58) LMNAAKT1ESR1ADORA3CDC25A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8318865-B2 Eye lens material and method of manufacturing thereof SHISEIDO COMPANY, LTD. (JP) 2012-11-27 US claimed
US-8277834-B2 Method for producing protein adsorption-preventing ocular lens material SHISEIDO COMPANY, LTD. (JP) 2012-10-02 US claimed
WO-2025029860-A1 DRUG CONJUGATES AND METHODS OF PREPARING AND USING THE SAME ADCENTRX THERAPEUTICS INC. (US) 2025-02-06 WO disclosed
US-20230257485-A1 GLYCOPHOSPHOLIPID POLYMERIC NETWORK AND USE THEREOF JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT 2023-08-17 US disclosed
US-11673974-B2 Glycophospholipid polymeric network and use thereof BAUSCH & LOMB INCORPORATED (US) 2023-06-13 US disclosed
US-8318865-B2 Eye lens material and method of manufacturing thereof SHISEIDO COMPANY, LTD. (JP) 2012-11-27 US disclosed
US-8277834-B2 Method for producing protein adsorption-preventing ocular lens material SHISEIDO COMPANY, LTD. (JP) 2012-10-02 US disclosed
EP-1750127-B1 Method of affinity separation. SHISEIDO CO LTD (JP) 2011-07-20 EP disclosed
US-20090321358-A1 Affinity Particle And Method Of Affinity Separation SHISEIDO COMPANY, LTD. (JP) 2009-12-31 US disclosed
US-20080300369-A1 Eye Lens Material and Method of Manufacturing Thereof SHISEIDO COMPANY, LTD. (JP) 2008-12-04 US disclosed
US-20080300375-A1 Ocular Lens Material and Method for Producing Same ISHIHARA, KAZUHIKO (10% OWNERSHIP) (JP) 2008-12-04 US disclosed
US-20080038221-A1 Method For Producing Protein Adsorption-Preventing Ocular Lens Material SHISEIDO COMPANY, LTD. (JP) 2008-02-14 US disclosed
US-20070241054-A1 Affinity Particle And Method Of Affinity Separation SHISEIDO COMPANY, LTD. (JP) 2007-10-18 US disclosed
EP-1750127-A1 AFFINITY PARTICLE AND METHOD OF AFFINITY SEPARATION Shiseido Company, Limited (JP) 2007-02-07 EP disclosed
EP-1750158-A1 OCULAR LENS MATERIAL AND METHOD FOR PRODUCING SAME Shiseido Company, Limited (JP) 2007-02-07 EP disclosed
EP-1750159-A1 OCULAR LENS MATERIAL AND METHOD FOR PRODUCING SAME Shiseido Company, Limited (JP) 2007-02-07 EP disclosed
EP-1750160-A1 METHOD FOR PRODUCING PROTEIN ADSORPTION-PREVENTING OCULAR LENS MATERIAL Shiseido Company, Limited (JP) 2007-02-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11673974-B2 Glycophospholipid polymeric network and use thereof ALG1, CSGALNACT1, FUT5 LMNA 2758/4885AKT1 4039/4885ESR1 3941/4885
US-20230257485-A1 GLYCOPHOSPHOLIPID POLYMERIC NETWORK AND USE THEREOF ALG1, CSGALNACT1, FUT6 LMNA 2560/4885AKT1 3377/4885ESR1 2552/4885
US-20080038221-A1 Method For Producing Protein Adsorption-Preventing Ocular Lens Material PCTP, CRYAA, PHOSPHO1 LMNA 557/4885AKT1 718/4885ESR1 4860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.